Tirzepatide and Surgery: What to Know Before a Procedure

There is a question on the preoperative intake form that did not exist several years ago, and a substantial number of patients still answer it incorrectly. It asks, in one wording or another, whether the patient takes a GLP-1 medication. Some people skip it because they do not think of tirzepatide as a medication in the way they think of a blood pressure tablet, others because a prescription obtained through a telehealth service sits mentally apart from the care their surgeon manages, and others because a weekly injection taken on a Sunday does not feel connected to a procedure scheduled for the following Thursday.

The disclosure matters for a reason that is mechanically straightforward. Tirzepatide slows gastric emptying, which is the rate at which food leaves the stomach and passes into the small intestine, and that effect is not incidental, since it contributes directly to the prolonged fullness patients describe and to how the therapy influences appetite. The same effect means that the assumption underlying standard surgical fasting instructions, namely that several hours without food leaves an empty stomach, does not hold as reliably as it does in patients who are not on this class of medication. What follows explains the mechanism, describes how professional guidance has shifted since 2023, and sets out what patients should disclose and when.

At a glance

Tirzepatide and other GLP-1 receptor agonists delay gastric emptying, so food may remain in the stomach beyond the usual fasting window. Under general anesthesia and deep sedation the reflexes that protect the airway are suppressed, and residual stomach contents can be regurgitated and aspirated into the lungs. Consensus guidance issued by the American Society of Anesthesiologists in 2023 recommended holding the medication before elective procedures, which for a weekly agent such as tirzepatide meant roughly a week. Guidance developed jointly by several professional societies and released in late 2024 moved away from routine discontinuation, so most patients on a stable dose can now expect to continue treatment, with a clear liquid diet in the 24 hours beforehand and an adapted anesthetic plan carrying much of the safety burden. The decision belongs to the surgical and anesthesia team, and the essential patient action is early disclosure rather than any unilateral change to the medication.

Why gastric emptying sits at the center of the question

Under general anesthesia, and to a lesser extent under deep sedation, the reflexes that normally keep stomach contents out of the airway stop functioning, since the gag reflex is suppressed and the lower esophageal sphincter relaxes. If material sitting in the stomach travels back up the esophagus, there is no reliable mechanism preventing it from entering the trachea and the lungs. That event is known as pulmonary aspiration, and although it is uncommon, it is among the more serious complications encountered in anesthetic practice because it can cause chemical injury to lung tissue, pneumonia, and in some cases respiratory failure.

The entire structure of preoperative fasting exists to prevent that outcome, and the conventional instruction of no solid food for eight hours with clear liquids permitted up to two hours beforehand rests on population data describing how long a typical stomach takes to clear. GLP-1 receptor agonists alter the inputs to that calculation, because slowing the rate at which the stomach empties extends the window during which residual content may still be present. Imaging and ultrasound studies have identified solid material in the stomachs of patients taking these medications who had fasted according to standard instructions, and while the finding is neither universal nor uniform in magnitude, it has been consistent enough to change clinical practice.

Two factors that change the size of the effect

Duration of therapy. The delay in gastric emptying is most pronounced when treatment begins and in the period following each dose increase, and it tends to attenuate over subsequent months as the body adapts, a phenomenon described in the literature as tachyphylaxis. A patient eighteen months into a stable maintenance dose therefore occupies a different position from someone three weeks into an initial titration step, which is why the length of time on therapy is one of the first things a preoperative assessment will establish.

Current symptom burden. Active nausea, vomiting, early satiety, bloating, or a persistent sense that meals are sitting undigested all function as clinical signals that emptying is meaningfully delayed at the present moment. These symptoms carry more weight than any general assumption about the drug class, because they describe what is happening in a particular patient rather than what happens on average, and they are among the most useful pieces of information a patient can supply before a procedure.

How the guidance changed

In June 2023 the American Society of Anesthesiologists issued consensus based guidance recommending that GLP-1 receptor agonists be held before elective procedures, with daily formulations withheld for one day and weekly formulations such as tirzepatide withheld for one week, and with standard fasting rules applied otherwise. That recommendation was an appropriately cautious response to a newly recognized and poorly quantified risk, and it was explicitly labeled as consensus rather than evidence based, because the supporting evidence had not yet been generated.

The practical consequences were considerable, since holding a weekly medication for a week before surgery creates a genuine gap in therapy. For patients using tirzepatide as part of glycemic management, that gap carries metabolic costs, and for patients partway through a titration schedule, an interruption can mean restarting at a lower dose and repeating the gastrointestinal adjustment period. Patients whose procedures were scheduled at short notice were often unable to comply at all.

In October 2024 a guidance document developed jointly by the American Society of Anesthesiologists together with several gastroenterology and bariatric organizations revised the position substantially, framing the matter around the principle that most patients can continue their GLP-1 medication before a procedure. The emphasis shifted from routine discontinuation toward risk stratification and preparation, which in practice means identifying the patients who carry elevated risk, having those patients follow a clear liquid diet for 24 hours beforehand, and allowing the anesthesia team to adjust technique accordingly. The earlier approach attempted to eliminate the variable by removing the drug, whereas the current approach accepts that the variable exists and manages it directly, reflecting both a larger body of evidence and a recognition that interrupting effective metabolic therapy carries costs of its own.

What elevated risk tends to mean

Current guidance directs additional caution toward patients whose gastric emptying is most likely to be substantially delayed, and the features that raise concern fall into a short list. Recent initiation or recent dose escalation matters because the delay is largest in the weeks following a starting dose or a titration step, so a procedure scheduled during a dose increase is worth flagging specifically. Higher doses matter because the effect appears to be related to dose, and a patient at the upper end of the tirzepatide range is generally regarded as carrying more risk than one on a low maintenance dose.

Active gastrointestinal symptoms provide the most direct evidence available, since nausea, vomiting, abdominal distension, or the persistent feeling that food is not moving indicate delayed emptying in that patient at that time regardless of how long therapy has continued. Coexisting conditions that independently slow motility compound the effect, and these include longstanding diabetes with autonomic involvement, known gastroparesis, and certain neurological conditions. Patients without these features, on a stable dose and free of symptoms, are generally considered lower risk, and they form the group most likely to be advised to continue the medication as scheduled.

The clear liquid approach in the final 24 hours

The central practical recommendation for patients assessed as higher risk is a clear liquid diet for the 24 hours preceding the procedure, followed by the standard fasting period. The reasoning is direct, since clear liquids leave the stomach considerably faster than solids and continue to do so even when emptying is slowed. By removing solid food from the whole day before rather than only from the preceding evening, the approach reduces the likelihood of residual solid material regardless of how delayed an individual patient's motility happens to be, and it accomplishes this without requiring the medication to be stopped.

Clear liquids in this context generally means water, clear broth, plain tea or coffee without milk or cream, clear juices without pulp, and gelatin, which is to say anything transparent enough to see through. The surgical team will provide a specific list, and patients managing blood glucose will receive instructions on how to handle carbohydrate intake during that window. Following the instructions issued by the team rather than a general list is important, because preoperative requirements vary by procedure and by institution.

The tools available to the anesthesia team

Beyond dietary preparation, the anesthesia team can adapt its own approach once it knows a GLP-1 medication is involved, and the most useful of these tools is gastric ultrasound performed at the bedside. Point of care ultrasound allows the anesthesiologist to examine the stomach directly before induction and assess whether meaningful content is present, which converts an assumption into an observation and is increasingly used for precisely this question. If the stomach appears empty the plan proceeds as normal, and if it does not, the plan changes.

Those changes can include a modified induction technique designed to secure the airway more rapidly, the use of a breathing tube rather than a supraglottic device, or in some cases postponement of an elective procedure. None of this is unusual, since these are standard techniques deployed whenever a patient is considered to have a full stomach, as happens routinely in emergency surgery. The relevant point for patients is that the team can only deploy them if it knows the medication is on board.

The recommendations shifted because the evidence improved, which means patients are not expected to track the guidance themselves. They are expected to make sure the clinicians who do track it know exactly what they are taking.

What patients should actually do

The single most important action is disclosure, and it needs to happen early, which means at the preoperative appointment or when the procedure is scheduled rather than on the morning of surgery when the anesthesiologist first meets the patient. Disclosure should be specific, so naming the medication, stating the current dose, saying when the last injection was given, noting any recent dose increase, and describing current gastrointestinal symptoms honestly all contribute to a usable clinical picture. A statement such as "tirzepatide, ten milligrams, last dose Sunday, increased from seven and a half about three weeks ago, still experiencing some early fullness" is genuinely informative, whereas describing it as a weight loss injection is not.

Medications prescribed through telehealth services need to be included, and this deserves stating plainly because it represents a common gap, since virtual care prescriptions are frequently absent from the medication list a surgical team is working from and the team has no way of knowing unless the patient says so. Once instructions are issued, they should be followed without improvisation, which means neither stopping the medication independently because of something read elsewhere nor continuing it independently on the grounds that the guidance has changed. Both decisions belong to the clinicians managing the procedure, who have access to considerations that general guidance cannot address, including the type of surgery, the depth of anesthesia planned, the patient's glycemic control, and the urgency of the operation. When a dose is held, it is worth asking specifically when to restart afterward, since that detail is easily overlooked during a discharge conversation.

This applies to procedures that patients do not always classify as surgery, including colonoscopy and upper endoscopy, dental work performed under sedation, cosmetic procedures, and imaging studies requiring sedation, because anything involving general anesthesia or deep sedation raises the same question.